Biological Markers for the Diagnosis of Central Nervous System Infective Diseases

• Conditions: Infection

• Registration Number: NCT02278016
• Lead Sponsor: Xijing Hospital

Brief Summary

Bacterial meningitis is a potentially life-threatening disease that is associated with substantial neurological morbidity and mortality. Accurate diagnosis is essential to improve outcome and prevent antibiotic overuse. Here we try to explore new biological markers for the diagnosis of the central nervous system infection disease.

Detailed Description

To investigate the diagnosis value of procalcitonin,interleukin-6, agiotensininⅡin the cerebrospinal fluid in the central nervous system infection disease.

Study Timeline

• Study Start: 2014-08
• Study First Submitted: 2014-10-27
• Study First Submitted QC: 2014-10-27
• Study First Posted: 2014-10-29
• Status Verified: 2015-12
• Last Update Submitted: 2015-12-31
• Last Update Posted: 2016-01-01
• Primary Completion: 2016-07
• Study Completion: 2017-07

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Aged 13 years or older;
2. At least two of the following clinical characteristics:headache, fever, neck stiffness, mental symptoms or consciousness impairment or seizures
3. Patients' family signed informed consent.

Exclusion Criteria

1. Contraindications to lumbar puncture
2. Patients with active malignancy

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Levels of procalcitonin, interleukin-6, agiotensininⅡ in the serum and cerebrospinal fluid	36 months	meet the clinical diagnostic criteria for the central nervous system infection disease, the blood and cerebrospinal fluid samples after onset.

Trial Locations

Locations (1)

Xijing Hospital; 🇨🇳 Xian, Shaanxi, China